Schrodinger's initial product, Jaguar, provides solutions to the Schrodinger equation, the fundamental equation describing molecular structure and energetics. Jaguar has a 5-10X performance advantage over its competition, and at present is used in nearly all major US pharmaceutical companies.

In December 1998, Schrodinger acquired rights to the MacroModel technology, developed by Clark Still at Columbia and marketed through Columbia up to that time. This acquisition also involved a significant venture capital investment, and incorporation of all of the key personnel on the MacroModel development team into Schrodinger.

Schrodinger's Scientific Advisory Board members have world class expertise in biomolecular modeling and simulation. This has focused the company on the development of novel computational methods for drug discovery - a central objective of Schrodinger's development plan during the past year and a half. Furthermore, computational modules for structural and functional genomics, specifically focused on fold recognition and homology modeling, are under development as well. These tools have been validated via successful entry into the CASP4 protein structure prediction contest.